Diagnosis and prognosis of breast and ovarian cancer A population-based study of 234 women

The diagnosis and prognosis for 135 women with breast cancer and 99 women with ovarian cancer in a well-defined geographical area, and a follow-up of 7–15 years are described, based on patients’ records. Diagnosis was initiated in primary care for 53% of women with breast cancer, and for 57% of women with ovarian cancer. Median patient delay was 1 week for breast cancer, and 3.5 weeks for ovarian cancer patients, and median provider delay was 3 weeks for both groups. Crude, relative, and corrected 5-year survival was 73%, 91%, and 82% in breast cancer, and 40%, 49%, and 43% in ovarian cancer. Cox multiple regression analyses showed that stage IIIA and IV, and young age were associated with impaired disease-related survival in breast cancer. In patients with ovarian cancer, stages III and IV at diagnosis, old age, and systemic symptoms dominating at presentation were predictive of reduced disease-related survival while a family history of cancer was predictive of increased survival.

[1]  Zhao Rui,et al.  Use of serological proteomic methods to find biomarkers associated with breast cancer , 2003, Proteomics.

[2]  G Dhom,et al.  Patient delay and stage of diagnosis among breast cancer patients in Germany – a population based study , 2002, British Journal of Cancer.

[3]  B. Storer,et al.  Factors associated with outcome after unrelated marrow transplantation for treatment of acute lymphoblastic leukemia in children. , 2002, Blood.

[4]  E. Petricoin,et al.  Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.

[5]  J. Herod,et al.  Effect of delays in primary care referral on survival of women with epithelial ovarian cancer: retrospective audit , 2002, BMJ : British Medical Journal.

[6]  A. Ramirez,et al.  A qualitative study of delay among women reporting symptoms of breast cancer. , 2001, The British journal of general practice : the journal of the Royal College of General Practitioners.

[7]  F. Frassoni,et al.  Increased risk of leukemia relapse with high dose cyclosporine after allogeneic marrow transplantation for acute leukemia: 10 year follow-up of a randomized study. , 2001, Blood.

[8]  G. Hédelin,et al.  Survival of women with breast cancer in France: variation with age, stage and treatment , 2001, Breast Cancer Research and Treatment.

[9]  A. Håkansson,et al.  Diagnostic Delay in Pediatric Malignancies - A Population-based Study , 2000, Acta oncologica.

[10]  D. Parkin,et al.  The performance of screening tests for ovarian cancer: results of a systematic review , 1999, British journal of obstetrics and gynaecology.

[11]  F. Merlo,et al.  Final height of patients who underwent bone marrow transplantation for hematological disorders during childhood: a study by the Working Party for Late Effects-EBMT. , 1999, Blood.

[12]  Steven J Skates,et al.  Screening for ovarian cancer: a pilot randomised controlled trial , 1999, The Lancet.

[13]  B. Haward,et al.  Effect on survival of delays in referral of patients with breast-cancer symptoms: a retrospective analysis , 1999, The Lancet.

[14]  P. Littlejohns,et al.  Influence of delay on survival in patients with breast cancer: a systematic review , 1999, The Lancet.

[15]  P. Ljungman,et al.  Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation Group. , 1999, Blood.

[16]  E. Shaoul,et al.  Cloning and characterization of a lymphoid-specific, inducible human protein tyrosine phosphatase, Lyp. , 1999, Blood.

[17]  B. Weber,et al.  BRCA1 and BRCA2: from molecular genetics to clinical medicine. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J. Ranstam,et al.  Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  P. DiSilvestro,et al.  Prognostic value of clinical variables in ovarian cancer. , 1997, Journal of clinical epidemiology.

[20]  J. Rodriguez-Sierra,et al.  Younger women with breast carcinoma have a poorer prognosis than older women , 1996, Cancer.

[21]  G. Hale,et al.  Unrelated donor bone marrow transplantation for children with relapsed acute lymphoblastic leukaemia in second complete remission , 1996, British journal of haematology.

[22]  M. Labopin,et al.  A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia , 1996, British journal of haematology.

[23]  T. Risberg,et al.  Diagnostic delay causes more psychological distress in female than in male cancer patients. , 1996, Anticancer research.

[24]  G. Dini,et al.  Role of busulfan and total body irradiation on growth of prepubertal children receiving bone marrow transplantation and results of treatment with recombinant human growth hormone. , 1995, Blood.

[25]  F. Pettersson,et al.  Symptoms and diagnostic difficulties in ovarian epithelial cancer , 1993, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[26]  F. Appelbaum The influence of total dose, fractionation, dose rate, and distribution of total body irradiation on bone marrow transplantation. , 1993, Seminars in oncology.

[27]  C. la Vecchia,et al.  Descriptive epidemiology of ovarian cancer in Europe , 1993, Gynecologic oncology.

[28]  J. Reiffers,et al.  Influence of the fractionation of total body irradiation on complications and relapse rate for chronic myelogenous leukemia. The Groupe d'Etude des greffes de moelle osseuse (GEGMO). , 1991, International journal of radiation oncology, biology, physics.

[29]  S. Groshen,et al.  Allogeneic bone marrow transplantation after hyperfractionated total-body irradiation and cyclophosphamide in children with acute leukemia. , 1987, The New England journal of medicine.

[30]  H. Deeg,et al.  Marrow transplantation for acute nonlymphoblastic leukemia in first remission: toxicity and long-term follow-up of patients conditioned with single dose or fractionated total body irradiation. , 1986, Bone marrow transplantation.

[31]  P. Neiman,et al.  CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.

[32]  J. Ferlay,et al.  Estimates of cancer incidence and mortality in Europe in 1995. , 2002, European journal of cancer.

[33]  R. Hultborn,et al.  The diagnosis of cancer in the "roar" of potential cancer symptoms of patients in primary health care. Research by means of the computerised journal. , 2001, Scandinavian journal of primary health care.

[34]  J. Klein,et al.  Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  L. Skoog,et al.  The general mammography screening program in Stockholm. Organisation and first-round results. , 1994, Acta oncologica.

[36]  H. Sommer,et al.  Patient's and doctor's delay in primary breast cancer. Prognostic implications. , 1994, Acta oncologica.

[37]  J. Sanders Endocrine problems in children after bone marrow tranplant for hematologic malignancies , 1991 .

[38]  N. Einhorn†,et al.  Symptomatology of ovarian cancer. , 1988, European journal of obstetrics, gynecology, and reproductive biology.

[39]  T. Hakulinen,et al.  A computer program package for relative survival analysis. , 1985, Computer programs in biomedicine.